Advertisement
The superior performance and clinical benefits of Masimo SET pulseoximetry technology are proven everyday at thousands of hospitals, andreinforced by more than 100 independent and objective studies demonstratingthat Masimo provides the most reliable SpO2 and pulse rate measurements evenunder the most challenging clinical conditions, including patient motion andlow peripheral perfusion.
Advertisement
Masimo is so confident in its ability to provide clinicians with the bestperforming pulse oximetry technology, the company is backing up its technologywith a $1 million performance guarantee for hospitals planning to upgradetheir pulse oximetry technology hospital-wide. If Masimo SET does notoutperform Nellcor in an objective side-by-side clinical evaluation, Masimowill pay the hospital up to $1 million to acquire Nellcor's pulse oximetry.Additional performance guarantee details can be found online athttp://www.masimo.com.
Joe E. Kiani, Founder and CEO of Masimo, stated; "The Fact vs. Fictionwebsite was developed in response to reports about Nellcor's constant andaggressive dissemination of false information to clinicians. The websiteexposes Nellcor fictions and delivers facts backed by proof. Our dedicationand commitment to 'improving patient outcomes and reducing cost of care bytaking noninvasive monitoring to new sites and applications' means that we notonly owe it to care providers to innovate breakthroughs in noninvasivemonitoring, but we must also do our part to educate, and sometimes even exposeobfuscations and falsehoods."
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies thatsignificantly improve patient care -- helping solve "unsolvable" problems. In1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulseoximetry, known as Masimo SET, which virtually eliminated false alarms andincreased pulse oximetry's ability to detect life-threatening events. Morethan 100 independent and objective studies demonstrate Masimo SET provides themost reliable SpO2 and pulse rate measurements even under the most challengingclinical conditions, including patient motion and low peripheral perfusion. In2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthroughnoninvasive blood constituent monitoring platform that can measure many bloodconstituents that previously required invasive procedures. Rainbow SETcontinuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygencontent (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), andPVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusionindex (PI), allowing early detection and treatment of potentiallylife-threatening conditions. Founded in 1989, Masimo has the mission of"Improving Patient Outcomes and Reducing Cost of Care by Taking NoninvasiveMonitoring to New Sites and Applications." Additional information about Masimoand its products may be found at http://www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined inSection 27A of the Securities Act of 1933 and Section 21E of the SecuritiesExchange Act of 1934, in connection with the Private Securities LitigationReform Act of 1995. These forward-looking statements are based on currentexpectations about future events affecting us and are subject to risks anduncertainties, all of which are difficult to predict and many of which arebeyond our control and could cause our actual results to differ materially andadversely from those expressed in our forward-looking statements as a resultof various risk factors, including, but not limited to: risks related to ourbelief that Masimo SET is superior to all other commercially-available pulseoximetry technologies, and risks related to our assumption that truthsasserted in the 'Fact vs. Fiction' website (http://www.nellcorfiction.com)will serve to substantially increase awareness of Nellcor fictions and/orMasimo's superiority, as well as other factors discussed in the "Risk Factors"section of our Quarterly Report on Form 10-Q for the fiscal quarter ended June28, 2008, filed with the Securities and Exchange Commission ("SEC") on August5, 2008, which may be obtained for free at the SEC's website athttp://www.sec.gov. Although we believe that the expectations reflected in ourforward-looking statements are reasonable, we do not know whether ourexpectations will prove correct. All forward-looking statements included inthis press release are expressly qualified in their entirety by the foregoingcautionary statements. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of today's date. We do notundertake any obligation to update, amend or clarify these forward-lookingstatements or the "Risk Factors" contained in our Quarterly Report on Form10-Q for the fiscal quarter ended June 28, 2008, whether as a result of newinformation, future events or otherwise, except as may be required under theapplicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and ReducingCost of Care by Taking Noninvasive Monitoring to New Sites and Applications,Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeterare trademarks or registered trademarks of Masimo Corporation.
SOURCE Masimo Corporation
